Educational Symposium
Targeting the Pathophysiology of Hyperphosphatemia in ESKD: From Physiology to Clinical Innovation
October 25, 2024 | 12:45 PM - 01:45 PM
Location: Marriott Grand Ballroom 5, Marriott Marquis
Session Description
Hyperphosphatemia is a cardinal complication of ESKD and is associated with many adverse outcomes, including cardiovascular disease and bone disease. Control of hyperphosphatemia remains challenging despite improved understanding of the mechanisms underlying the disorder. Furthermore, attempts to control hyperphosphatemia leave patients struggling with a diminished quality of life due to both high pill burden from phosphate binders and the dietary restrictions which limit palatability and nutritive value of food.This symposium highlights the pathophysiology of hyperphosphatemia, reviews the limitations of the current treatment landscape, and explores new treatment options for hyperphosphatemia in ESKD.
Support is provided by an educational grant from Ardelyx, Inc.
Learning Objective(s)
- Identify pathophysiological mechanisms contributing to hyperphosphatemia in ESKD
- Discuss the complications associated with hyperphosphatemia in ESKD and the barriers to successful management of hyperphosphatemia
- Describe dietary and pharmaceutical approaches to control of hyperphosphatemia in ESKD
Learning Pathway(s)
- Bones‚ Stones‚ and Mineral Metabolism
- Dialysis
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Mechanisms of Hyperphosphatemia in ESKD: The Interplay of Physiology, Diet, and Pharmacotherapy
12:55 PM - 01:15 PM
- Hyperphosphatemia in ESKD: Is It Time for a Therapeutic Paradigm Shift?
01:15 PM - 01:35 PM
- Audience Q&A
01:35 PM - 01:45 PM